Albinterferon alfa-2b

N/A

Report date: 2022/07/06 17:25:57

Base Information

Drug NameAlbinterferon alfa-2b
Drug Alias Name阿干扰素α-2bAlbumin-interferon alfaalbinterferonum alfa-2bAlbumin/interferon-alpha fusion proteinInterferon-alpha/albumin fusion protein +[13] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionImmunostimulantsInnate antiviral immune response inducersInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsHepatitis C, ChronicHepatitis CHepatitis B, Chronic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[29] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Pharma AgHuman Genome Sciences IncNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsN/A
Inactive IndicationsHepatitis C, ChronicHepatitis CHepatitis B, Chronic +[4] 

Other Information

ATC CodeL03AB12
Related LinksN/A